Skip to main content

Advertisement

Table 3 Participant characteristics at study enrollment in Machinga, Nkhotakota, and Karonga Districts, in Malawi, 2014, restricted to participants with parasitemia at enrollment <200,000 parasites/μL (n = 426)

From: In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated Plasmodium falciparum malaria in Malawi, 2014

Characteristic AL ASAQ
Total (n = 321) Site Total (n = 105)
Machinga (n = 112) Nkhotakota (n = 104) Karonga (n = 105)
Age, months (median, range)*, † 31 (6, 58) 35 (7, 58) 27 (6, 57) 32 (6, 57) 38 (9, 59)
Male, n (%)* 170 (53) 67 (59.8) 46 (44) 57 (54.3) 43 (41)
Participant slept under ITN previous night, n (%)†, a 258 (82.2) 101 (91) 64 (64) 93 (90.3) 85 (85)
Weight (kg) (mean, SD) 11.3 (3.5) 11.9 (3.1) 11.3 (2.2) 10.7 (4.8) 11.6 (3.5)
Haemoglobin (g/dL) (mean, SD) 9.7 (2.4) 9.4 (3.2) 9.7 (1.8) 10.1 (1.6) 9.9 (1.8)
Anaemia (Hb ≤ 11.0 g/dL) 250 (78) 99 (88.4) 78 (75) 73 (70) 79 (75.2)
Parasitaemia (parasites/μL) (geometric mean, range)b 31,888 (1098, 198,789) 25,700 (1100, 198,000) 32,860 (1393, 198,789) 40,135 (2066, 199,187) 25,952 (1019, 197,701)
  1. All participants were eligible for enrollment based on initial parasitaemia (1000–200,000 parasites/μL); however, 26 (6.1 %) participants had parasitaemia higher than 200,000 parasites/μL according to slide reviews done after study completion
  2. * Significant difference between study arms (p < 0.05); significant difference between study sites (p < 0.05)
  3. aInsecticide-treated bed net;
  4. bAsexual parasitaemia.